MSL
IOVA icon

Mackay Shields LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Mackay Shields LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,000
Closed -$659K – 1487
2020
Q2 		$659K Sell
24,000
-49,138
-67% -$1.62M 0.01% 1135
2020
Q1 		$2.19M Sell
73,138
-5,300
-7% -$140K 0.02% 631
2019
Q4 		$2.17M Sell
78,438
-4,800
-6% -$109K 0.02% 843
2019
Q3 		$1.51M Sell
83,238
-3,200
-4% -$70.8K 0.01% 1015
2019
Q2 		$2.12M Buy
86,438
+43,820
+103% +$660K 0.01% 876
2019
Q1 		$405K Buy
42,618
+9,100
+27% +$88.4K ﹤0.01% 1224
2018
Q4 		$297K Sell
33,518
-982
-3% -$9.47K ﹤0.01% 1249
2018
Q3 		$388K Buy
+34,500
New +$490K ﹤0.01% 1033

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Mackay Shields LLC's IOVA Position: Q3 2020 in Review

Mackay Shields LLC sold out of Iovance Biotherapeutics (IOVA) in Q3 2020, closing a stake of 24,000 shares — an estimated $659K sold.

Mackay Shields LLC first reported a position in IOVA in Q3 2018 and held it in 8 quarters. The position peaked at $2.19M in Q1 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • Mackay Shields LLC reported no remaining Iovance Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Mackay Shields LLC sold 24,000 Iovance Biotherapeutics shares in Q3 2020, an estimated $659K.
  • Mackay Shields LLC first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 8 quarters.
  • Mackay Shields LLC's Iovance Biotherapeutics position peaked at $2.19M in Q1 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on Mackay Shields LLC's 13F filing for Q3 2020, filed 4 Nov 2020.